Literature DB >> 16014000

The pharmacogenetics of coumarin therapy.

Deepak Voora1, Howard L McLeod, Charles Eby, Brian F Gage.   

Abstract

Vitamin K antagonists (coumarins) are widely-used oral anticoagulants for the prevention of venous thromboembolism and strokes. Wide inter-individual variation in dose response and frequent bleeds characterize the initiation of coumarin therapy. Over the past 10 years both genetic and nongenetic determinants of coumarin dose response have been identified. A comprehensive pharmacogenetics approach to warfarin therapy has the potential to improve the safety and efficiency of warfarin initiation.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16014000     DOI： 10.2217/14622416.6.5.503

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  15 in total

1.  Evaluation of a reverse-hybridization StripAssay for the detection of genetic polymorphisms leading to acenocoumarol sensitivity.

Authors:  Argyri Gialeraki; Christos Markatos; Elisabeth Grouzi; Efrosyni Merkouri; Anthi Travlou; Marianna Politou
Journal:  Mol Biol Rep       Date:  2009-06-28       Impact factor: 2.316

2.  Limited clinical utility of genotype-guided warfarin initiation dosing algorithms versus standard therapy: a meta-analysis and trial sequential analysis of 11 randomized controlled trials.

Authors:  H L Tang; W L Shi; X G Li; T Zhang; S D Zhai; H G Xie
Journal:  Pharmacogenomics J       Date:  2015-04-14       Impact factor: 3.550

3.  Quantitative Assessment of CYP2C9 Genetic Polymorphisms Effect on the Oral Clearance of S-Warfarin in Healthy Subjects.

Authors:  Chanan Shaul; Simcha Blotnick; Mordechai Muszkat; Meir Bialer; Yoseph Caraco
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

4.  The hepatoprotective effect of coumarin and coumarin derivates on carbon tetrachloride-induced hepatic injury by antioxidative activities in rats.

Authors:  Mukadder Atmaca; Hakkı Murat Bilgin; Basra Deniz Obay; Hüda Diken; Mustafa Kelle; Ebru Kale
Journal:  J Physiol Biochem       Date:  2011-06-09       Impact factor: 4.158

Review 5.  Nodular Thyroid Disease and Thyroid Cancer in the Era of Precision Medicine.

Authors:  Carles Zafon; Juan J Díez; Juan C Galofré; David S Cooper
Journal:  Eur Thyroid J       Date:  2017-03-03

6.  Therapeutic potential of 7,8-dimethoxycoumarin on cisplatin- and ischemia/reperfusion injury-induced acute renal failure in rats.

Authors:  Arunachalam Muthuraman; Shailja Sood; Muthusamy Ramesh; Karan Deep Singh Puri; Anil Peters; Ashish Chauhan; Pradeep Kumar Arora; Ajay Rana
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-04-15       Impact factor: 3.000

Review 7.  Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems.

Authors:  Jian-Ming Lü; Peter H Lin; Qizhi Yao; Changyi Chen
Journal:  J Cell Mol Med       Date:  2009-09-14       Impact factor: 5.310

Review 8.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

Review 9.  Clinical translation of genotyping and haplotyping data: implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping.

Authors:  Ioannis S Vizirianakis
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

10.  Exploring cardioprotective potential of esculetin against isoproterenol induced myocardial toxicity in rats: in vivo and in vitro evidence.

Authors:  Chitikela P Pullaiah; Vinod K Nelson; Sushma Rayapu; Narasimha Kumar G V; Thyagaraju Kedam
Journal:  BMC Pharmacol Toxicol       Date:  2021-07-15       Impact factor: 2.483
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.